A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).
Kunle Odunsi(University of Chicago), Rafael G. Amado(Ghent University Hospital), Arundathy N. Bartlett-Pandite, Brian M. Slomovitz(Mount Sinai Medical Center), Mihaela Cristea(City Of Hope National Medical Center), Erin Van Winkle, Oliver Dorigo(Cancer Prevention Institute of California), Karen Chagin, Malini Iyengar, Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Elliot Norry, Gabor Kari
Cited by 10
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2008|852
Tumor-infiltrating NY-ESO-1–specific CD8 <sup>+</sup> T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
|Proceedings of the National Academy of Sciences|2010|844